Regeneron Pharmaceuticals: all 411 studies

Page 4 of 5. Open to participants first (93), then studies with results posted, then the rest; newest registration first within each.

• Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult VolunteersTerminatedNCT04616105Phase 1
• Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy VolunteersTerminatedNCT04616079Phase 1
• T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten ChallengeCompletedNCT04614571Not applicable
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult VolunteersCompletedNCT04601844Phase 1
• Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)WithdrawnNCT04577820Phase 3
• Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19CompletedNCT04519437Phase 1
• Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)Active, not recruitingNCT04515524
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult HumansCompletedNCT04506645Phase 1
• Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult ParticipantsCompletedNCT04491838Phase 1
• Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor MalignanciesTerminatedNCT04465487Phase 1
• REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive TherapyTerminatedNCT04409080Phase 1
• Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin LymphomaWithdrawnNCT04373083Phase 2
• Registry of Asthma Patients Initiating DUPIXENT®CompletedNCT04287621
• Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic DermatitisCompletedNCT04287608
• Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer TreatmentCompletedNCT04262336Phase 1
• Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected PregnancyCompletedNCT04173442
• First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)CompletedNCT04083534Phase 1/2
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung CancerActive, not recruitingNCT04077099Phase 1/2
• Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult ParticipantsCompletedNCT03969849Phase 1
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT03969004Phase 3
• An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)CompletedNCT03936335
• Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsActive, not recruitingNCT03916627Phase 2
• Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell CarcinomaCompletedNCT03889912Phase 1
• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruitingNCT03888105Phase 2
• CemiplimAb Survivorship EpidemiologyCompletedNCT03836105
• Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive MalignanciesTerminatedNCT03746704Phase 1
• Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisWithdrawnNCT03710941Phase 2
• Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy VolunteersCompletedNCT03645746Phase 1
• Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03580694Phase 1
• A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy VolunteersCompletedNCT03530514Phase 1
• Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaNo longer availableNCT03492489
• To Assess the Patients' Ability to Self-Administer FasinumabCompletedNCT03491904Phase 1
• Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung CancerCompletedNCT03438318Phase 1
• Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)Active, not recruitingNCT03428646
• Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance StudyTerminatedNCT03379558
• Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesActive, not recruitingNCT03233139Phase 1
• An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)CompletedNCT03198130Phase 1
• Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy VolunteersCompletedNCT03146416Phase 1
• Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy VolunteersCompletedNCT03115996Phase 1
• Study of REGN3500 and Dupilumab in Patients With AsthmaCompletedNCT03112577Phase 1
• Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced MelanomaCompletedNCT03084640Phase 1
• Study of Dupilumab Auto-injector Device When Used by Patients With Atopic DermatitisCompletedNCT03050151Phase 1
• Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced CancersCompletedNCT03005782Phase 1
• An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)CompletedNCT03002376Phase 1
• Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate AsthmaCompletedNCT02999711Phase 1
• A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult SubjectsCompletedNCT02958436Phase 1
• Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult MenCompletedNCT02943239Phase 1
• A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477CompletedNCT02870400Phase 1
• Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy SubjectsCompletedNCT02828397Phase 1
• Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult VolunteersCompletedNCT02777151Phase 1
• Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid TumorsTerminatedNCT02744287Phase 1
• Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy SubjectsCompletedNCT02741739Phase 1
• Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyCompletedNCT02680184Phase 1
• A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell MalignanciesCompletedNCT02651662Phase 1
• Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)CompletedNCT02647086Phase 1
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Active, not recruitingNCT02612454Phase 3
• Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical StudyWithdrawnNCT02520245Phase 1
• Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian SubjectsCompletedNCT02516618Phase 1
• Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or HipCompletedNCT02447276Phase 2/3
• Study of REGN2810 (Anti-PD-1) in Patients With Advanced MalignanciesCompletedNCT02383212Phase 1
• Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesCompletedNCT02290951Phase 1
• Study of REGN1193 in Patients With Type 2 Diabetes MellitusTerminatedNCT02284425Phase 1
• Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult ParticipantsCompletedNCT02127801Phase 1
• Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult VolunteersCompletedNCT02121080Phase 1
• Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500CompletedNCT02107872Phase 1
• Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)CompletedNCT02097524Phase 1
• Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMDCompletedNCT02061865Phase 1
• Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)CompletedNCT01997164Phase 1
• Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With SarcopeniaCompletedNCT01963598Phase 2
• An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193CompletedNCT01933763Phase 1
• Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult SubjectsCompletedNCT01922661Phase 1
• Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)CompletedNCT01910220Phase 1
• Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy VolunteersCompletedNCT01893528Phase 1
• Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT01803321Phase 1
• Study to Assess the Safety and Tolerability of Single Doses of REGN1500CompletedNCT01749878Phase 1
• Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of CancerCompletedNCT01727869Phase 1
• Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)CompletedNCT01720576Phase 1
• Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid MalignanciesCompletedNCT01688960Phase 1
• Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic DermatitisTerminatedNCT01605708Phase 1/2
• Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy VolunteersCompletedNCT01540539Phase 1
• A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)CompletedNCT01507402Phase 1
• Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy VolunteersCompletedNCT01484600Phase 1
• Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic DermatitisCompletedNCT01385657Phase 1
• Study of Nesvacumab (REGN910/ SAR307746)CompletedNCT01271972Phase 1
• Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic DermatitisCompletedNCT01259323Phase 1
• A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the KneeWithdrawnNCT01239017Phase 2
• Safety and Tolerability Study of REGN846 (SAR302352) in Healthy VolunteersCompletedNCT01209793Phase 1
• Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy VolunteersCompletedNCT01197391Phase 1
• A Study of Tocilizumab in Patients With Rheumatoid ArthritisCompletedNCT01187563
• Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant AtorvastatinCompletedNCT01161082Phase 1
• Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy VolunteersCompletedNCT01074372Phase 1
• Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid ArthritisCompletedNCT01055899Phase 1
• Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal InjuryWithdrawnNCT01053702Phase 2
• Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy VolunteersCompletedNCT01026597Phase 1
• A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid ArthritisCompletedNCT01026519Phase 1
• Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy VolunteersCompletedNCT01015027Phase 1
• A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis SubjectsCompletedNCT01011959Phase 1
• Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis PainTerminatedNCT01001923Phase 2
• Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture PainTerminatedNCT01001715Phase 2
• A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic PainCompletedNCT00991172Phase 2

← Regeneron Pharmaceuticals overview and focus areas